DigitalHealth InvestorTalk Show

Eddie delivers a handful of genuinely useful insights - payer inertia explained through rebate incentives, the patient-perception gap vs. drugs, and the lean-vs.-pharma-analogy model - but they're buried under the host's very long monologues on MagSafe hardware, Mac Studios, Jason Calacanis, and generic macro commentary that crowd out signal for long stretches.

“I've literally had executives at the, some of these payers go, yeah, but it's drugs. We know how to do drugs. We just don't know how to do this.”

“The best inflection that the Endeavor products had was when right near the end of my time, we released what's called the Focus Score, which is a very deep, really deep science product of a couple years of R and D that was actually able to show people how much you're focusing”

The payer-rebate structural explanation and the cruel irony of side effects making drugs feel credible are genuinely non-obvious insights from direct practitioner experience; the psychedelics-as-PDT-analogy is also a fresh frame. However, much of the episode recycles familiar takes on AI sycophancy, down-market company-building, and conference-budget waste.

“we've actually had, I've, uh, been in meetings where they said, can you triple the price of the product? Because it'll help us justify this. Which is a crazy thing that the average patient would be horrified to hear.”

“drugs are able to list rebates, whereas these types of products are not just statutorily. And so you can't book savings, which means you can't book profit as easily. And they're cheaper products, which actually works against them.”

Eddie Martucci is a legitimate practitioner - founding CEO of the first FDA-cleared prescription digital therapeutic company, PhD in drug discovery, now running a stealth cancer biotech - and he speaks with the earned specificity of someone who actually sat in payer executive meetings and shepherded products through FDA. The host's frequent long monologues dilute total guest airtime significantly.

“when I left Achille two years ago, we had two different commercial models that were being used in every state in the country”

“I think now the endeavor products have crossed, you know, outside of my hands or leadership have crossed over a hundred thousand patients treated. That's real use and real scale.”

Eddie supplies concrete numbers when he speaks - Resilience Care's 200 clinical centers, 30,000+ patients, 35% ER reduction, 2-3 months additional chemo adherence, Akili's 100k+ treated patients - but the host's extended macro section leans on narrative and vague SaaS multiples without sourcing, and many company references are name-drops without depth.

“it's in 200 clinical centers, over 30,000 patients used. The outcomes are more time on treatment, right? Two to three months more on chemo... it decreased things like emergency room visits by 35%”

“the SaaS Capital Index... 3.8 times... substantially below the number just in December which was 5.8 times in December... during the boom this index got as high as 30 times”

The host asks a few structurally sound questions (payer justification, what went well vs. not in PDT) and occasionally creates space for Eddie's best material, but consistently undercuts the conversation with multi-minute personal monologues on MagSafe rings, Mac Studios, and conference logistics, and rarely pushes back on or probes Eddie's claims.

“So he is both trying to agentize every single one of these steps to the greatest extent possible. But he's also buying a bunch of Mac studios and Mac minis and trying to running not just for their agentic ability but to run models on them.”

“what do you think is their, is their claim with respect to most prescription digital therapeutics, is it those two things or are they saying something else? It doesn't work or. We looked at the data, we think it doesn't work. Why are they justifying.”